US5232929A
(en)
|
1990-11-28 |
1993-08-03 |
Pfizer Inc. |
3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
|
US5364943A
(en)
*
|
1991-11-27 |
1994-11-15 |
Pfizer Inc. |
Preparation of substituted piperidines
|
PT533280E
(pt)
|
1991-09-20 |
2001-01-31 |
Glaxo Group Ltd |
Novas utilizacoes medicas para antagonistas de taquiquinina
|
EP0641328B1
(en)
*
|
1992-05-18 |
2001-11-21 |
Pfizer Inc. |
Bridged aza-bicyclic derivatives as substance p antagonists
|
US5688804A
(en)
*
|
1992-08-04 |
1997-11-18 |
Pfizer Inc. |
3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists
|
DE69331103T2
(de)
*
|
1992-08-19 |
2002-03-14 |
Pfizer |
Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
|
WO1994013663A1
(en)
*
|
1992-12-10 |
1994-06-23 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
|
FR2700472B1
(fr)
|
1993-01-19 |
1995-02-17 |
Rhone Poulenc Rorer Sa |
Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
|
US5340826A
(en)
*
|
1993-02-04 |
1994-08-23 |
Pfizer Inc. |
Pharmaceutical agents for treatment of urinary incontinence
|
US5635510A
(en)
*
|
1993-05-06 |
1997-06-03 |
Merrell Pharmaceuticals Inc. |
Substituted pyrrolidin-3-yl-alkyl-piperidines
|
US5393762A
(en)
*
|
1993-06-04 |
1995-02-28 |
Pfizer Inc. |
Pharmaceutical agents for treatment of emesis
|
EP0653208A3
(en)
*
|
1993-11-17 |
1995-10-11 |
Pfizer |
Substance P antagonists for the treatment or prevention of sunburn.
|
EP0659409A3
(en)
*
|
1993-11-23 |
1995-08-09 |
Pfizer |
Substance P antagonists for the inhibition of angiogenesis.
|
EP0655246A1
(en)
*
|
1993-11-30 |
1995-05-31 |
Pfizer Inc. |
Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
|
ATE177095T1
(de)
|
1994-08-25 |
1999-03-15 |
Merrell Pharma Inc |
Substituierte piperidine für die behandlung von allergischen krankheiten
|
FR2728169A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
|
FR2728166A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Composition topique contenant un antagoniste de substance p
|
FR2728165A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
|
KR100414321B1
(ko)
*
|
1995-04-13 |
2004-02-18 |
아벤티스 파마슈티칼스 인크. |
타치키닌수용체길항활성을갖는신규한치환된피페라진유도체
|
TW458774B
(en)
|
1995-10-20 |
2001-10-11 |
Pfizer |
Antiemetic pharmaceutical compositions
|
US6211199B1
(en)
|
1995-11-17 |
2001-04-03 |
Aventis Pharmaceuticals Inc. |
Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
|
FR2741262B1
(fr)
|
1995-11-20 |
1999-03-05 |
Oreal |
Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
|
US6194406B1
(en)
|
1995-12-20 |
2001-02-27 |
Aventis Pharmaceuticals Inc. |
Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
|
US6423704B2
(en)
|
1995-12-20 |
2002-07-23 |
Aventis Pharmaceuticals Inc. |
Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
|
US5932571A
(en)
*
|
1996-02-21 |
1999-08-03 |
Hoechst Marion Roussel, Inc. |
Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
|
US5998439A
(en)
*
|
1996-02-21 |
1999-12-07 |
Hoescht Marion Roussel, Inc. |
Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
|
US5922737A
(en)
*
|
1996-02-21 |
1999-07-13 |
Hoechst Marion Roussel, Inc. |
Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
|
JP2001172178A
(ja)
*
|
1999-10-25 |
2001-06-26 |
Pfizer Prod Inc |
偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン
|
EP1246806B1
(en)
|
1999-11-03 |
2008-02-27 |
AMR Technology, Inc. |
Arly- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
EA005409B1
(ru)
*
|
2000-04-10 |
2005-02-24 |
Пфайзер Продактс Инк. |
Производные бензамидопиперидина в качестве антагонистов рецепторов вещества p
|
US7119207B2
(en)
*
|
2000-04-10 |
2006-10-10 |
Pfizer Inc |
Benzoamide piperidine containing compounds and related compounds
|
WO2002004455A2
(en)
|
2000-07-11 |
2002-01-17 |
Albany Molecular Research, Inc |
4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
|
US20020049211A1
(en)
*
|
2000-09-06 |
2002-04-25 |
Sobolov-Jaynes Susan Beth |
Combination treatment for depression and anxiety
|
EP1192952A3
(en)
*
|
2000-09-28 |
2003-03-26 |
Pfizer Products Inc. |
Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
|
KR101389246B1
(ko)
|
2004-07-15 |
2014-04-24 |
브리스톨-마이어스스퀴브컴파니 |
아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
BRPI0516602A
(pt)
*
|
2004-10-18 |
2008-09-16 |
Lilly Co Eli |
composto, e, composição farmacêutica
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
KR101594898B1
(ko)
|
2005-07-15 |
2016-02-18 |
알바니 몰레큘라 리써치, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2946778A1
(en)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
EP2247185B1
(en)
|
2008-03-03 |
2014-04-16 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
WO2010132437A1
(en)
|
2009-05-12 |
2010-11-18 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
JP5739415B2
(ja)
|
2009-05-12 |
2015-06-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
(S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
|
EA020553B1
(ru)
|
2009-05-12 |
2014-12-30 |
Олбани Молекьюлар Рисерч, Инк. |
7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
|
MX2012004377A
(es)
|
2009-10-14 |
2012-06-01 |
Merck Sharp & Dohme |
Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
EP2601293B1
(en)
|
2010-08-02 |
2017-12-06 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US20140045832A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Insulin-Like Growth Factor-1 Receptor Inhibitors
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
MX2015004041A
(es)
|
2012-09-28 |
2015-07-06 |
Merck Sharp & Dohme |
Compuestos novedosos que son inhibidores de erk.
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
US8846657B2
(en)
|
2012-12-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3986886A2
(en)
*
|
2019-06-19 |
2022-04-27 |
Grünenthal GmbH |
Substituted pyrrolidine amides v
|